NYSE •
Healthcare •
Biotechnology •
Quote as of 06/05/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization38.28 mln
Float31.04 mln
Earnings Date08/07/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
7
/ 100
Severely lagging
Debt / Equity
0.66
Moderate leverage
ROE
-171
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Actinium Pharmaceuticals is a New York-based company focused on developing targeted radiation treatments for patients with cancer and other serious blood disorders, particularly those who have not responded to standard therapies. Its pipeline includes treatments for acute myeloid leukemia, prostate cancer, and conditions like sickle cell disease, as well as a conditioning agent designed to improve the safety and success of bone marrow transplants. The company also works alongside the National Cancer Institute to advance several of its programs and continues to explore new treatment options for solid tumors.